


REMARKS

No questions of new matter are raised by the above amendment. Entry of the above amendment is therefore respectfully requested.

If there are any fees due in connection with the filing of this response, please charge the fees to deposit Account No. 50-0925. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such extension is requested and should also be charged to our Deposit Account.

Respectfully submitted,



Luke A. Kilyk
Registration No. 33,251

Attorney Docket No. 3190-010
KILYK & BOWERSOX, P.L.L.C.
53A Lee Street
Warrenton, VA 20186
(540) 428-1701

0936895-09191
T06T50"E5689860

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

1. (Amended) A bone resorption inhibitor ~~comprising~~ [which contains] leukocyte activating protein factor[-showing] or leukocyte activating protein factor-derived substances, in an amount effective ~~for~~ [activity to] bone resorption inhibitory activity.

3. (Amended) The bone resorption inhibitor according to claim 1 [or 2], wherein the leukocyte activating protein factor or leukocyte activating protein factor-derived substances inhibits against osteoclast cell activity.

4. (Amended) The bone resorption inhibitor according to claim 1 [any of claims 1-3], ~~wherein said substances have an~~ [where in an effective compound shows] inhibitory activity of more than 80% at a concentration of 10 $\mu\text{g/ml}$ using percent inhibition of pit formation [in the screening methods pit formation, in candidate substances].

5. (Amended) A screening method [methods] for bone resorption inhibitor [inhibitors] derived substances containing leukocyte activating protein factor or leukocyte activating protein factor-derived substances, which are purified from the source of these substances, or which are prepared or synthesized by based on the information of these substances, comprising determining bone resorption inhibitory activity using percent inhibition of pit formation.

6. (Amended) A method to produce bone resorption inhibitors comprising introducing [Use of] leukocyte activating protein factor or leukocyte activating protein factor-derived substances in the production of bone resorption inhibitors.

7. (Amended) A ~~method~~ [methods] for bone resorption inhibiting in ~~an animal comprising administering to said animal~~, [animals with] bone resorption ~~inhibitor~~ [inhibitors] derived substances containing leukocyte activating protein factor or leukocyte activating protein factor-derived substances.

09868953-091901